• EN

    • -+ 0.00%
    -+ 0.00%
    -+ 0.00%

    Why Repligen (RGEN) Is Up 6.9% After Mixed Q2 2026 Results With Higher Revenue And Lower EPS

    Simply Wall St·08/01/2026 09:32:34
    Listen to the news
    • In the past week, Repligen Corporation reported second-quarter 2026 results showing revenue of US$204.13 million, up from US$182.37 million a year earlier, while net income fell to US$5.01 million from US$14.87 million and diluted EPS from continuing operations declined to US$0.09 from US$0.26.
    • Although profitability compressed even as revenue increased, analysts have responded by revising earnings estimates higher and maintaining a positive stance on Repligen’s longer-term earnings power.
    • We’ll now examine how Repligen’s revenue growth alongside weaker earnings reshapes the existing investment narrative and risk–reward trade-off for investors.

    This technology could replace computers: discover 26 stocks that are working to make quantum computing a reality.

    Repligen Investment Narrative Recap

    To own Repligen, you have to believe its bioprocessing tools can convert steady revenue gains into more consistent profitability. The latest quarter complicates that picture: revenue rose to US$204.13 million but net income and EPS contracted, keeping margin pressure as the key near term risk. For now, that does not appear to materially change the main short term catalyst, which is whether higher analyst earnings estimates prove justified as 2026 unfolds.

    Among recent developments, the index removals on June 27, 2026 stand out in the context of softer earnings. Being dropped from several Russell growth benchmarks can influence trading volumes and short term sentiment, even if it does not alter the underlying business. For investors watching how quickly profit margins recover, this combination of weaker Q2 earnings and potential shifts in shareholder base adds another angle to the near term risk reward balance.

    Yet even with analysts once projecting earnings of about US$156 million on US$1.1 billion of revenue by 2028, you should still be watching the risk that...

    Read the full narrative on Repligen (it's free!)

    Repligen's narrative projects $1.2 billion revenue and $159.5 million earnings by 2029. This requires 14.7% yearly revenue growth and about a $118 million earnings increase from $41.5 million today.

    Uncover how Repligen's forecasts yield a $182.05 fair value, a 29% upside to its current price.

    Exploring Other Perspectives

    RGEN 1-Year Stock Price Chart
    RGEN 1-Year Stock Price Chart

    Before this Q2 report, the most optimistic analysts were effectively betting on Repligen more than doubling revenue to about US$1.1 billion and lifting earnings to roughly US$156 million within a few years, which is a far more aggressive path than the baseline narrative and could look very different if margin pressure tied to regulatory and approval headwinds persists.

    Explore 3 other fair value estimates on Repligen - why the stock might be worth as much as 29% more than the current price!

    Form Your Own Verdict

    Don't just follow the ticker - dig into the data and build a conviction that's truly your own.

    Ready To Venture Into Other Investment Styles?

    Our daily scans reveal stocks with breakout potential. Don't miss this chance:

    This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.